RGLS Past Earnings image   This RGLS past earnings page last updated 11/11/2022
RGLS Past Earnings
PeriodPast Earnings DateGAAP
Q3 202211/10/2022-0.500
Q2 20228/11/2022-0.500
Q1 20225/12/2022-0.500
Q4 20213/10/2022-0.700
Q3 202111/10/2021-1.000
Q2 20218/10/2021-0.800
Q1 20215/13/2021-0.800
Q4 20203/9/2021-0.300
Q3 202011/5/2020-0.400
Q2 20208/13/2020-2.300
Q1 20205/14/2020-2.500
Q4 20193/12/2020-2.300
Q3 201911/12/2019-2.600
Q2 20198/8/2019-3.000
Q1 20195/9/2019-3.100
Q4 20183/18/2019-9.800
Q3 201811/8/2018-11.800
Q2 20188/9/2018-15.600
Q1 20185/10/2018-18.000
Q4 20173/7/2018-16.800
Q3 201711/7/2017-21.600
Q2 20178/1/2017-49.200
Q1 20175/4/2017-45.600
Q4 20163/2/2017-45.600
Q3 201611/1/2016-44.400
Q2 20168/2/2016-48.000
Q1 20165/2/2016-48.000
Q4 20152/22/2016-16.800
Q3 201511/5/2015-30.000
Q2 20158/4/2015-49.200
Q1 20155/7/2015-34.800
Q4 20142/18/2015-24.000
Q3 201411/5/2014-31.200
Q2 20148/6/2014-34.800
Q1 20145/8/2014-3.000
Q4 20132/27/2014-1.100
Q3 201311/13/2013-0.700
Q2 20138/13/2013-1.900
Q1 20135/14/2013-2.000
Q4 20122/20/2013-2.200
RGLS Past Revenue
PeriodPast Earnings DateGAAP
Q3 202211/10/2022NA
Q2 20228/11/2022NA
Q1 20225/12/2022NA
Q4 20213/10/2022NA
Q3 202111/10/2021NA
Q2 20218/10/2021NA
Q1 20215/13/2021NA
Q4 20203/9/20210.01B
Q3 202011/5/20200.01B
Q2 20208/13/2020NA
Q1 20205/14/20200.01M
Q4 20193/12/20200.02M
Q3 201911/12/20190.02M
Q2 20198/8/20190.02M
Q1 20195/9/20190.01B
Q4 20183/18/201918000
Q3 201811/8/201818000
Q2 20188/9/201818000
Q1 20185/10/201818000
Q4 20173/7/201818000
Q3 201711/7/201718000
Q2 20178/1/201718000
Q1 20175/4/201718000
Q4 20163/2/201718000
Q3 201611/1/2016204000
Q2 20168/2/2016483000
Q1 20165/2/2016489000
Q4 20152/22/201610.86M
Q3 201511/5/20151.86M
Q2 20158/4/20153.83M
Q1 20155/7/20154.20M
Q4 20142/18/20154.22M
Q3 201411/5/20141.10M
Q2 20148/6/2014736000
Q1 20145/8/20141.60M
Q4 20132/27/20145.45M
Q3 201311/13/20136.12M
Q2 20138/13/20134.76M
Q1 20135/14/20130.00B
Q4 20122/20/20133.24M
Quotes delayed 20 minutes

Email EnvelopeFree RGLS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Regulus Therapeutics (RGLS) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

RGNX Past Earnings
RIGL Past Earnings
RLAY Past Earnings
RLMD Past Earnings
RLYB Past Earnings
RMD Past Earnings
RMED Past Earnings
RMTI Past Earnings
RNA Past Earnings
RNAZ Past Earnings

RGLS Past Earnings Q&A

What was the best and worst RGLS past earnings results?
For Regulus Therapeutics, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest RGLS past earnings result in our data set was -0.300/share posted in Q4 2020, while the lowest was in Q2 2017 when RGLS posted -49.200/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q4 2015 when RGLS reported 10.86M in revenue, while the quarter with the lowest revenue in our data set was Q3 2022 at NA of revenue.

  Suggested answer: There are 40 RGLS past earnings results in our data set.

On this page we presented the RGLS past earnings date information for Regulus Therapeutics. Reviewing that RGLS Past Earnings for the company, we see that the highest past earnings result in our data set was in Q4 2020, when RGLS posted gaap of -0.300/share. Meanwhile the lowest RGLS past earnings result was in Q2 2017, when RGLS posted gaap of -49.200/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q4 2015 when RGLS reported 10.86M in revenue, while the smallest revenue quarter was Q3 2022 when RGLS reported NA in revenue.

Any self directed investor doing their due diligence on RGLS or any other given stock can benefit from researching all of the Regulus Therapeutics past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate Regulus Therapeutics past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for RGLS. Thanks for visiting, and the next time you need to research RGLS past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: Kimco Realty 13F Filers, Institutional Holders of YAYO, Top Ten Hedge Funds Holding IMOM.

 

RGLS Past Earnings | www.PastEarnings.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in PastEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.